144. MSG-15: Pharmacokinetic (PK), Adverse Events (AEs), and Tolerability Data from an Open Label Randomized Clinical Trial (RCT) Comparing Oral Suba-itraconazole (SUBA-ITC) to Conventional Itraconazole (C-ITC) for Treatment of Endemic Mycosis (EM)

BACKGROUND: C-ITC is a drug of choice for non-life-threatening, non-CNS histoplasmosis, blastomycosis, sporotrichosis, coccidioidomycosis and other EM. Oral C-ITC is problematic due to inconsistent absorption often leading to sub-therapeutic serum levels. SUBA-ITC is an FDA approved formulation whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Pappas, Peter G, Spec, Andrej, Miceli, Marisa H, Proia, Laurie, Arauz, Ana Belen, Hayes, Justin, Peinhardt, Alisa, McMullen, Rachel, Moore, Mary K, McGwin, Gerald, Thompson III, George R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778035/
http://dx.doi.org/10.1093/ofid/ofaa439.454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778035/
http://dx.doi.org/10.1093/ofid/ofaa439.454

Ejemplares similares